Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 3/20 | 0.62 |
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 0.57 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 2/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
| ▸ | TERT | O14746 | 3/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.46 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.46 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.46 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.46 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | GSR | P00390 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17637516 | 0.95 | LTA4H (0.56) | LTA4HSPHK1SPHK2MMP2MMP9 | |
| SCHEMBL17661962 | 0.95 | LTA4H (0.56) | LTA4HSPHK1SPHK2MMP2MMP9 | |
| SCHEMBL19234733 | 0.87 | LTA4H (0.60) | LTA4HSPHK1SPHK2MMP2MMP9 | |
| SCHEMBL26266218 | 0.85 | SPHK1 (0.68) | SPHK1SPHK2S1PR1S1PR3S1PR4 | |
| SCHEMBL20715656 | 0.85 | LTA4H (0.58) | LTA4HSPHK1SPHK2MMP2MMP9 | |
| SCHEMBL24395095 | 0.85 | SPHK1 (0.57) | LTA4HSPHK1SPHK2S1PR1S1PR3 | |
| SCHEMBL14850430 | 0.85 | SPHK1 (0.57) | LTA4HSPHK1SPHK2S1PR1S1PR3 | |
| SCHEMBL16847450 | 0.84 | SPHK1 (0.53) | LTA4HSPHK1SPHK2S1PR1S1PR3 | |
| SCHEMBL26464130 | 0.84 | LTA4H (0.60) | LTA4HSPHK1SPHK2MMP2MMP9 | |
| SCHEMBL25333060 | 0.83 | SPHK1 (0.56) | LTA4HSPHK1SPHK2S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2396036-B1 | IMMUNOCONJUGATES WITH AN INTRACELLULARLY-CLEAVABLE LINKAGE | IMMUNOMEDICS INC (US) | 2017-06-28 | — | — | EP | disclosed |
| US-20170151356-A1 | Camptothecin Conjugates of Anti-CD22 Antibodies for Treatment of B Cell Diseases | IMMUNOMEDICS, INC. | 2017-06-01 | — | — | US | disclosed |
| US-20170151356-A1 | Camptothecin Conjugates of Anti-CD22 Antibodies for Treatment of B Cell Diseases | IMMUNOMEDICS, INC. | 2017-06-01 | — | — | US | disclosed |
| WO-2014092804-A1 | DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY | IMMUNOMEDICS, INC. (US) | 2014-06-19 | — | — | WO | disclosed |
| WO-2010093395-A1 | IMMUNOCONJUGATES WITH AN INTRACELLULARLY-CLEAVABLE LINKAGE | IMMUNOMEDICS, INC. (US) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170151356-A1 | Camptothecin Conjugates of Anti-CD22 Antibodies for Treatment of B Cell Diseases | CD22, CD2, CD2BP2 | LTA4H 1815/4885SPHK1 1602/4885SPHK2 1140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.